Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

not_yet_recruiting133%
recruiting267%

Recent Activity

2 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066
recruitingphase_1

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

NCT05413421
recruiting

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

NCT06652607

Clinical Trials (3)

Showing 3 of 3 trials
NCT07333066Phase 3

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Not Yet Recruiting
NCT05413421Phase 1

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Recruiting
NCT06652607

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3